EntryPoint Capital LLC Makes New $223,000 Investment in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

EntryPoint Capital LLC bought a new stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 10,431 shares of the company’s stock, valued at approximately $223,000. EntryPoint Capital LLC owned approximately 0.07% of Jasper Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of JSPR. FMR LLC acquired a new stake in Jasper Therapeutics in the third quarter valued at approximately $722,000. BNP Paribas Financial Markets grew its holdings in Jasper Therapeutics by 208.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock valued at $47,000 after purchasing an additional 1,698 shares in the last quarter. MetLife Investment Management LLC increased its stake in Jasper Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock worth $129,000 after buying an additional 3,873 shares during the period. Verition Fund Management LLC acquired a new position in Jasper Therapeutics in the 3rd quarter worth $477,000. Finally, Samsara BioCapital LLC boosted its position in Jasper Therapeutics by 11.4% in the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock valued at $10,997,000 after buying an additional 59,642 shares during the last quarter. 79.85% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Royal Bank of Canada dropped their target price on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research report on Thursday, January 9th. UBS Group began coverage on Jasper Therapeutics in a research report on Thursday, February 13th. They issued a “buy” rating and a $38.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. BMO Capital Markets initiated coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They issued an “outperform” rating and a $63.00 price target on the stock. Finally, JMP Securities reissued a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a report on Monday, January 6th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Jasper Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $62.50.

Jasper Therapeutics Stock Down 7.9 %

Shares of NASDAQ:JSPR opened at $4.46 on Friday. The company has a market cap of $67.00 million, a PE ratio of -0.94 and a beta of 2.23. Jasper Therapeutics, Inc. has a fifty-two week low of $4.38 and a fifty-two week high of $31.01. The firm has a 50-day simple moving average of $5.69 and a 200 day simple moving average of $14.77.

Jasper Therapeutics (NASDAQ:JSPR) last posted its earnings results on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.35). As a group, research analysts forecast that Jasper Therapeutics, Inc. will post -4.47 EPS for the current fiscal year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.